Crinetics Pharmaceuticals Announces $350M Common Stock Offering to Fund Commercial Launch and R&D
CRNX sits 97% above its 52-week low of $24.1 on elevated volume (3.4× avg).
Summary
Crinetics Pharmaceuticals is conducting a $350 million common stock offering, with an option for an additional $52.5 million, to finance the commercial launch of PALSONIFY and advance its R&D pipeline.
Key Events · Financing and Capital Events · CRNX
-
Common Stock Offering Announced
Crinetics Pharmaceuticals is offering $350.0 million of common stock, with underwriters having a 30-day option to purchase up to an additional $52.5 million in shares.
-
Strategic Use of Proceeds
Net proceeds will fund commercial activities for the launch of PALSONIFY, research and development of product candidates, other research programs, and general corporate purposes, including potential in-licensing or acquisitions.
-
Significant Dilution for Shareholders
The offering is expected to cause immediate and substantial dilution in the net tangible book value per share for current investors.
-
Preliminary Q4 2025 Revenue and Cash Position
The company reported estimated unaudited net product revenue from PALSONIFY of greater than $5.0 million for Q4 2025 and approximately $1.0 billion in cash, cash equivalents, and investment securities as of December 31, 2025.
Analysis · CRNX · Life Sciences
Crinetics Pharmaceuticals is undertaking a substantial common stock offering to raise $350 million, with an option for underwriters to purchase an additional $52.5 million. This capital raise, while providing significant funding for the company's strategic initiatives, will result in immediate and substantial dilution for existing shareholders. The proceeds are earmarked for critical commercial activities related to the launch of PALSONIFY and for advancing its research and development pipeline. This offering follows the company's preliminary report of over $5.0 million in PALSONIFY net revenue for Q4 2025 and an estimated $1.0 billion in cash, suggesting a strategic capital infusion for growth rather than a distressed raise.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRNX was trading at $47.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $24.10 to $57.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.